BRPI1005683A2 - processo livre de células in vitro de produção de um ácido desoxirribonucleio (dna) linear fechado, kit, método de indução de reação imunológica contra um antígeno em um hospedeiro, processo de elaboração de uma composição farmacêutica e uso de uma molécula de dna linear fechado na fabricação de um medicamento - Google Patents

processo livre de células in vitro de produção de um ácido desoxirribonucleio (dna) linear fechado, kit, método de indução de reação imunológica contra um antígeno em um hospedeiro, processo de elaboração de uma composição farmacêutica e uso de uma molécula de dna linear fechado na fabricação de um medicamento

Info

Publication number
BRPI1005683A2
BRPI1005683A2 BRPI1005683-1A BRPI1005683A BRPI1005683A2 BR PI1005683 A2 BRPI1005683 A2 BR PI1005683A2 BR PI1005683 A BRPI1005683 A BR PI1005683A BR PI1005683 A2 BRPI1005683 A2 BR PI1005683A2
Authority
BR
Brazil
Prior art keywords
dna
closed linear
kit
deoxyribonucleic acid
antigen
Prior art date
Application number
BRPI1005683-1A
Other languages
English (en)
Inventor
Hill Vanessa
Original Assignee
Touchlight Genetics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40469378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1005683(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Touchlight Genetics Limited filed Critical Touchlight Genetics Limited
Publication of BRPI1005683A2 publication Critical patent/BRPI1005683A2/pt
Publication of BRPI1005683B1 publication Critical patent/BRPI1005683B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6846—Common amplification features
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

processo livre de células in vitro de produção de um ácido desoxirribonucleico (dna) linear fechado, kit, método de indução de reação imunológica contra um antígeno em um hospedeiro, processo de elaboração de uma composição farmacêutica e uso de uma molécula de dna linear fechado na fabricação de um medicamento processo in vitro de produção de ácido desoxirribonucleico (dna) linear fechado compreende (a) contato de um modelo de dna que compreende pelo menos uma sequência alvo de protelomerase com pelo menos uma dna polimerase na presença de um ou mais primers sob condições que promovam a amplificação do mencionado modelo; e (b) contato de dna amplificado produzido em (a) com pelo menos uma protelomerase sob condições que promovam a formação de dna linear fechado. um kit fornece os componentes necessários no processo.
BRPI1005683-1A 2009-01-30 2010-02-01 processo in vitro, livre de células, para a produção de um ácido desoxirribonucleico (dna) linear fechado BRPI1005683B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0901593.4A GB0901593D0 (en) 2009-01-30 2009-01-30 Production of closed linear DNA
GB0901593.4 2009-01-30
PCT/GB2010/000165 WO2010086626A1 (en) 2009-01-30 2010-02-01 Production of closed linear dna

Publications (2)

Publication Number Publication Date
BRPI1005683A2 true BRPI1005683A2 (pt) 2019-04-02
BRPI1005683B1 BRPI1005683B1 (pt) 2019-11-12

Family

ID=40469378

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1005683-1A BRPI1005683B1 (pt) 2009-01-30 2010-02-01 processo in vitro, livre de células, para a produção de um ácido desoxirribonucleico (dna) linear fechado

Country Status (19)

Country Link
US (4) US9109250B2 (pt)
EP (3) EP2612925B1 (pt)
JP (2) JP2012516147A (pt)
KR (1) KR101926662B1 (pt)
CN (2) CN102301010B (pt)
AU (1) AU2010209532B2 (pt)
BR (1) BRPI1005683B1 (pt)
CA (1) CA2751130C (pt)
DK (2) DK2391731T3 (pt)
EA (1) EA021069B1 (pt)
ES (2) ES2400890T3 (pt)
GB (1) GB0901593D0 (pt)
IL (1) IL213930A (pt)
LT (1) LT3150722T (pt)
MX (1) MX2011007937A (pt)
NZ (1) NZ594004A (pt)
SG (1) SG173102A1 (pt)
WO (1) WO2010086626A1 (pt)
ZA (1) ZA201105013B (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2351294B8 (es) * 2009-07-02 2012-06-06 Consejo Superior De Investigaciones Científicas (Csic) Metodo para la replicación, amplificación, o secuenciación de un adn molde.
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
US9290800B2 (en) 2013-03-15 2016-03-22 Pacific Biosciences Of California, Inc. Targeted rolling circle amplification
GB201502645D0 (en) * 2015-02-17 2015-04-01 Touchlight Genetics Ltd Method
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
EP3701963A1 (en) 2015-12-22 2020-09-02 CureVac AG Method for producing rna molecule compositions
RU2616279C1 (ru) * 2015-12-28 2017-04-13 Федеральное государственное бюджетное учреждение науки Институт биохимии и генетики Уфимского научного центра Российской академии наук (ИБГ УНЦ РАН) Способ получения маркерных лестниц для гель-электрофоретического определения размеров фрагментов нуклеиновых кислот
US10077459B2 (en) 2016-05-04 2018-09-18 General Electric Company Cell-free protein expression using rolling circle amplification product
CN109844134B (zh) * 2016-08-16 2023-05-05 塔驰莱特Ip有限公司 闭合线性dna的生产
WO2019118806A1 (en) * 2017-12-14 2019-06-20 Solid Biosciences Inc. Non-viral production and delivery of genes
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
CN109971825B (zh) * 2017-12-28 2020-11-10 南京金斯瑞生物科技有限公司 快速制备桑格测序模板的方法
GB201805683D0 (en) 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
EP3810782A2 (en) * 2018-06-22 2021-04-28 Asklepios Biopharmaceutical, Inc. Vectors for gene delivery that persist within cells
JP7481755B2 (ja) * 2018-11-02 2024-05-13 ナイキジェン，リミテッド 組換えパルボウイルスベクターならびにその作製および使用方法
GB201905651D0 (en) * 2019-04-24 2019-06-05 Lightbio Ltd Nucleic acid constructs and methods for their manufacture
US12595501B2 (en) 2019-06-13 2026-04-07 Global Life Sciences Solutions Usa Llc Expression of products from nucleic acid concatemers
WO2020255010A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
US20250041386A1 (en) 2019-06-18 2025-02-06 Janssen Sciences Ireland Unlimited Company Recombinant Interleukin 12 Construct and Uses Thereof
WO2020254876A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Virus-like particle delivery of hepatitis b virus (hbv) vaccines
EP3986460A2 (en) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
CA3143679A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
KR20220041080A (ko) 2019-06-18 2022-03-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
KR20220042116A (ko) 2019-06-18 2022-04-04 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합
WO2020255062A1 (en) 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
EP3986457A1 (en) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines
EP3792367A1 (en) 2019-09-11 2021-03-17 Universität Bielefeld Method for the production of raav and method for the in vitro generation of genetically engineered, linear, single-stranded nucleic acid fragments containing itr sequences flanking a gene of interest
KR20220128607A (ko) 2019-09-18 2022-09-21 인터갈락틱 테라퓨틱스, 인크. 합성 dna 벡터 및 사용 방법
GB201915163D0 (en) 2019-10-18 2019-12-04 Univ Southampton Cancer vaccine
EP4077661A1 (en) 2019-12-20 2022-10-26 Keygene N.V. Ngs library preparation using covalently closed nucleic acid molecule ends
CN115315518A (zh) * 2020-01-17 2022-11-08 阿斯克肋匹奥生物制药公司 重组aav的生产
CN115023503A (zh) * 2020-01-31 2022-09-06 泰瑞斯疗法公司 生产闭合线性dna的方法
CN116209756A (zh) 2020-03-04 2023-06-02 旗舰先锋创新Vi有限责任公司 调控基因组的方法和组合物
GB202007428D0 (en) 2020-05-19 2020-07-01 Fabricnano Ltd Polynucleotide synthesis
CA3181680A1 (en) 2020-06-12 2021-12-16 University Of Rochester Encoding and expression of ace-trnas
CA3189358A1 (en) 2020-08-26 2022-03-03 Scancell Limited Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen
WO2022074058A1 (en) 2020-10-06 2022-04-14 Keygene N.V. Targeted sequence addition
US20240150793A1 (en) 2021-03-29 2024-05-09 Kaneka Corporation Vector, linear covalently closed dna production method using vector, parvovirus vector production method, and parvovirus-vector-producing cell production method
MX2023014228A (es) 2021-06-08 2024-01-25 Touchlight Ip Ltd Vector lentiviral.
GB202108176D0 (en) 2021-06-08 2021-07-21 Touchlight Ip Ltd Vector
AU2022299552A1 (en) 2021-06-25 2024-01-04 Oxford Biomedica (Us) Llc Adeno-associated virus packaging systems
CA3226725A1 (en) 2021-07-13 2023-01-19 Stonehaven Incubate AG Composition and uses thereof
EP4124660A1 (en) 2021-07-30 2023-02-01 4basebio, S.L.U. Linear dna with enhanced resistance against exonucleases and methods for the production thereof
AU2022343268A1 (en) 2021-09-08 2024-03-28 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
GB202114105D0 (en) 2021-10-01 2021-11-17 Fabricnano Ltd Nucleotide synthesis
WO2023069948A1 (en) 2021-10-18 2023-04-27 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
WO2023114897A2 (en) 2021-12-15 2023-06-22 Homology Medicines, Inc. Methods and compositions for the production of adeno-associated virus
AU2022422134A1 (en) * 2021-12-23 2024-07-04 Generation Bio Co. Scalable and high-purity cell-free synthesis of closed-ended dna vectors
CN114561372B (zh) * 2022-04-27 2022-07-26 南京巨匠生物科技有限公司 Bst DNA聚合酶突变体及其应用和产品、基因、重组质粒和基因工程菌
EP4293101A1 (en) 2022-06-14 2023-12-20 Asklepios Biopharmaceutical, Inc. Reactor with temperature control and method of using the same
CN119698477A (zh) 2022-08-10 2025-03-25 镇江蓬勃生物科技有限公司 线性闭合dna的制备方法及该方法所用质粒
WO2024039652A1 (en) 2022-08-16 2024-02-22 Aldevron, L.L.C. Cell-free method of producing synthetic circular nucleic acid
EP4589008A1 (en) 2022-09-12 2025-07-23 Kaneka Corporation Double stranded circular dna vector, method for producing linear covalently closed dna, and fusion polypeptide containing protelomerase and endonuclease
EP4593877A1 (en) 2022-09-29 2025-08-06 Ceva Hampton Limited Vaccine construct and uses thereof
EP4612320A1 (en) 2022-11-02 2025-09-10 4basebio UK Ltd Purification of linear dna products
EP4365303A1 (en) 2022-11-02 2024-05-08 4basebio, S.L.U. Purification of linear dna products
KR102753513B1 (ko) * 2022-11-18 2025-01-13 최낙식 Direct RNA 추출 버퍼 및 이의 용도
WO2024121354A1 (en) 2022-12-08 2024-06-13 Keygene N.V. Duplex sequencing with covalently closed dna ends
EP4638776A1 (en) 2022-12-19 2025-10-29 Thermo Fisher Scientific GENEART GmbH Retrieval of sequence-verified nucleic acid molecules
EP4410995A1 (en) 2023-02-01 2024-08-07 4basebio, S.L.U. Linear dna with enhanced resistance against exonucleases and methods for the production thereof
ES3062031T3 (pt) 2023-02-01 2026-04-08 4Basebio Uk Ltd
WO2024197081A1 (en) 2023-03-20 2024-09-26 Hc Bioscience, Inc. Minimally-sized dna threads for trna therapy
CN116606834A (zh) * 2023-04-10 2023-08-18 天津中合基因科技有限公司 多种具有切割连接活性的原端酶及其应用
AU2024258816A1 (en) 2023-04-18 2025-10-23 Uniqure Biopharma B.V. Generation of adeno-associated virus capsid libraries for insect cells
WO2024256842A1 (en) 2023-06-16 2024-12-19 Touchlight IP Limited Therapeutic transfection
CN121816413A (zh) 2023-08-18 2026-04-07 镇江蓬勃生物科技有限公司 纯化核酸分子的方法
US11981936B1 (en) 2023-09-29 2024-05-14 New England Biolabs, Inc. TelA variants, compositions, and methods
EP4553156A1 (en) 2023-11-08 2025-05-14 4basebio UK Ltd Synthetic dna production using cas nuclease
GB202319998D0 (en) 2023-12-22 2024-02-07 Touchlight Ip Ltd duplexing method
EP4596713A1 (en) 2024-02-05 2025-08-06 4basebio UK Ltd Dna with enhanced resistance against exonucleases and methods for the production thereof
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee
WO2025194042A1 (en) 2024-03-14 2025-09-18 Affinia Therapeutics Inc. Plasmid system for production of recombinant adenoassociated virus
WO2025202929A1 (en) * 2024-03-29 2025-10-02 Pfizer Inc. Methods for producing nucleic acids
EP4729632A1 (en) 2024-10-18 2026-04-22 AskBio Inc. Method of synthesizing dna

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU649066B2 (en) 1990-07-25 1994-05-12 Syngene, Inc. Circular extension for generating multiple nucleic acid complements
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
US6953676B1 (en) 1992-05-01 2005-10-11 Trustees Of The University Of Pennsylvania Mesoscale polynucleotide amplification device and method
WO1994003624A1 (en) 1992-08-04 1994-02-17 Auerbach Jeffrey I Methods for the isothermal amplification of nucleic acid molecules
US5714320A (en) 1993-04-15 1998-02-03 University Of Rochester Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides
DE69429038T2 (de) 1993-07-28 2002-03-21 Pe Corporation (Ny), Norwalk Vorrichtung und Verfahren zur Nukleinsäurevervielfältigung
FR2732971B1 (fr) 1995-04-13 1997-07-04 Genset Sa Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
DK0862656T3 (da) 1995-11-21 2001-04-09 Univ Yale Unimolekylær segmentamplifikation og -detektering
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
JPH10234399A (ja) 1997-02-28 1998-09-08 Shinkinrui Kinou Kaihatsu Kenkyusho:Kk ピシウム属菌検出用の核酸配列
US6124120A (en) 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6054274A (en) * 1997-11-12 2000-04-25 Hewlett-Packard Company Method of amplifying the signal of target nucleic acid sequence analyte
EP1179585B1 (en) 1997-12-24 2008-07-09 Cepheid Device and method for lysis
US6620597B1 (en) 1998-01-09 2003-09-16 University Of Utah Research Foundation Method for in vitro amplification of circular DNA
DE19826758C1 (de) 1998-06-15 1999-10-21 Soft Gene Gmbh Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte
JP2002525049A (ja) 1998-09-15 2002-08-13 イェール ユニバーシティ ローリングサークル増幅を用いる分子クローニング
WO2001004280A2 (de) 1999-07-08 2001-01-18 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
EP1268856A2 (de) 2000-04-07 2003-01-02 Epigenomics AG Detektion von snp's und cytosin-methylierungen
GB0018120D0 (en) 2000-07-24 2000-09-13 Fermentas Ab Nuclease
US6977148B2 (en) 2001-10-15 2005-12-20 Qiagen Gmbh Multiple displacement amplification
US20030077611A1 (en) 2001-10-24 2003-04-24 Sention Methods and systems for dynamic gene expression profiling
US20030170693A1 (en) 2001-12-21 2003-09-11 George Chaconas Assay for identifying modulators of Borrelia telomere resolvase
US7081339B2 (en) 2002-04-12 2006-07-25 Primera Biosystems, Inc. Methods for variation detection
CA2492203A1 (en) 2002-07-12 2004-01-22 Affymetrix, Inc. Synthetic tag genes
US20040022764A1 (en) 2002-07-31 2004-02-05 Hanan Polansky Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
DE10393824D2 (de) * 2002-09-23 2005-08-11 Mologen Ag Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze
US7955795B2 (en) 2003-06-06 2011-06-07 Qiagen Gmbh Method of whole genome amplification with reduced artifact production
US7452699B2 (en) 2003-01-15 2008-11-18 Dana-Farber Cancer Institute, Inc. Amplification of DNA in a hairpin structure, and applications
ATE432365T1 (de) 2003-02-21 2009-06-15 Geneform Technologies Ltd Verfahren, kits und reagenzien zur nukleinsäuresequenzierung
EP1706502A4 (en) 2003-11-26 2007-05-23 Eppendorf Ag METHODS AND COMPOSITIONS FOR IN VITRO AMPLIFICATION OF EXTRACHROMOSOMIC NUCLEIC ACID
BRPI0515777A (pt) 2004-12-11 2008-08-05 Cytogenix Inc biossìntese isenta de células de ácido nucléico de alta qualidade e usos dos mesmos
EP1871897B1 (en) 2005-04-12 2010-09-29 Olink AB Methods for production of oligonucleotides
AU2006242387B2 (en) 2005-04-29 2011-01-06 Synthetic Genomics, Inc. Amplification and cloning of single DNA molecules using rolling circle amplification
CA2624324A1 (en) 2005-10-06 2007-04-19 Lucigen Corporation Thermostable viral polymerases and methods of use
ATE549408T1 (de) * 2006-01-12 2012-03-15 Lucigen Corp Lineare vektoren, wirtszellen und klonverfahren
CN101589157B (zh) 2006-10-06 2014-04-02 万达利亚研究公司 用于连续快速热循环系统的方法
WO2008151023A2 (en) * 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
US8921072B2 (en) 2008-09-02 2014-12-30 General Electric Compnay Methods to generate DNA mini-circles
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
US9114399B2 (en) 2010-08-31 2015-08-25 Canon U.S. Life Sciences, Inc. System and method for serial processing of multiple nucleic acid assays
EP2692870A1 (en) 2012-08-03 2014-02-05 Alacris Theranostics GmbH Method for nucleic acid amplification
KR102014989B1 (ko) 2013-04-15 2019-08-27 삼성전자주식회사 폴리뉴클레오티드 및 그의 용도

Also Published As

Publication number Publication date
CN102301010A (zh) 2011-12-28
US20150329902A1 (en) 2015-11-19
US11384388B2 (en) 2022-07-12
WO2010086626A1 (en) 2010-08-05
CN102301010B (zh) 2015-07-08
US20120282283A1 (en) 2012-11-08
EP3150722A1 (en) 2017-04-05
EA201101141A1 (ru) 2012-05-30
EP2612925B1 (en) 2016-11-30
IL213930A0 (en) 2011-07-31
JP6454243B2 (ja) 2019-01-16
KR20110107846A (ko) 2011-10-04
CN104911177A (zh) 2015-09-16
EP2391731B1 (en) 2013-01-23
AU2010209532A1 (en) 2011-07-28
ES2400890T3 (es) 2013-04-15
MX2011007937A (es) 2011-08-17
IL213930A (en) 2014-08-31
CA2751130A1 (en) 2010-08-05
EP2612925A1 (en) 2013-07-10
EA021069B1 (ru) 2015-03-31
JP2016047049A (ja) 2016-04-07
US9109250B2 (en) 2015-08-18
GB0901593D0 (en) 2009-03-11
BRPI1005683B1 (pt) 2019-11-12
DK3150722T3 (da) 2019-12-16
JP2012516147A (ja) 2012-07-19
DK2391731T3 (da) 2013-04-22
SG173102A1 (en) 2011-08-29
EP2391731A1 (en) 2011-12-07
US20220372565A1 (en) 2022-11-24
CA2751130C (en) 2018-03-06
NZ594004A (en) 2013-01-25
ZA201105013B (en) 2013-03-27
EP3150722B1 (en) 2019-09-11
KR101926662B1 (ko) 2018-12-07
HK1159693A1 (en) 2012-08-03
LT3150722T (lt) 2019-12-10
ES2749629T3 (es) 2020-03-23
AU2010209532B2 (en) 2015-06-25
US20190203282A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
BRPI1005683A2 (pt) processo livre de células in vitro de produção de um ácido desoxirribonucleio (dna) linear fechado, kit, método de indução de reação imunológica contra um antígeno em um hospedeiro, processo de elaboração de uma composição farmacêutica e uso de uma molécula de dna linear fechado na fabricação de um medicamento
de Soure et al. Scalable microcarrier-based manufacturing of mesenchymal stem/stromal cells
CL2020002805A1 (es) Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526)
BR112022003089A2 (pt) Métodos de produção de células progenitoras hemogênicas a partir de células-tronco pluripotentes
BR112012015576A2 (pt) "cerâmica de vidro de dissilicato de lítio, método para sua fabricação e seu uso"
Little et al. The effect of chondroitin sulphate and hyaluronic acid on chondrocytes cultured within a fibrin-alginate hydrogel
BRPI0611535A8 (pt) Métodos para processar células de microorganismos e células de levedura, composição, suplemento alimentar, produto farmacêutico, cosmético ou produto nutracêutico e ração animal
BR112012028805A2 (pt) composições de endorribonuclease e métodos de uso das mesmas.
BR112016005228A8 (pt) Uso de uma ou mais glicosidases e processo para produzir um oligossacarídeo
BR112015030918A2 (pt) método para produção de células progenitoras renais, e fármacos contendo células progenitoras renais
BR9915026A (pt) Móleculas de ácido nucléico codificando uma enzima ramificadora de bactérias do gênero neisseria bem como métodos para a produção de alfa-1,4 glicanos ramificados para alfa-1,6
WO2012142213A3 (en) Safe sequencing system
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
Marsico et al. Unraveling the consequences of oxygen imbalance on early embryo development: Exploring mitigation strategies
WO2014139885A3 (en) Molecular targets and inhibitors of said targets, useful in the treatment of diseases associated with epithelial mesenchymal transition
BR112012029271A2 (pt) fungo isolado, método para produzir e kit para fabricar pelo menos um composto selecionado do grupo que consite de 1, 8-cineol, 1-metil-1,4-cicloexadieno, e (+) -a-metileno-a-fenchocanforona, molécula de ácido nucleico isolada de um fungo,e, método para gerar cepas mutantes de um fungo.
BR112012033714A2 (pt) polipeptídeo com atividade de acetil xilano esterase e seus usos.
Smieszek et al. Obesity affects the proliferative potential of equine endometrial progenitor cells and modulates their molecular phenotype associated with mitochondrial metabolism
Szczupak et al. Escherichia coli tRNA 2-selenouridine synthase (SelU): elucidation of substrate specificity to understand the role of S-geranyl-tRNA in the conversion of 2-Thio-into 2-selenouridines in bacterial tRNA
Dittz et al. Antiangiogenesis, loss of cell adhesion and apoptosis are involved in the antitumoral activity of Proteases from V. cundinamarcensis (C. candamarcensis) in murine melanoma B16F1
Kokinos et al. Inhibition of cyclin-dependent kinases 8/19 restricts bacterial and virus-induced inflammatory responses in monocytes
Koutsakis et al. Sulfated Hyaluronan modulates the functional properties and matrix effectors expression of breast cancer cells with different estrogen receptor status
Apte et al. A methodological approach to identify natural compounds with antifibrotic activity and the potential to treat pulmonary fibrosis using single-cell sequencing and primary human lung macrophages
Russo et al. Evaluation of controlled ovarian stimulation protocols in patients with normal and low ovarian reserve: analyses of miRNAs and selected target genes involved in the proliferation of human cumulus cells and oocyte quality
Vizitiu et al. Mature miR-99a upregulation in the amniotic fluid samples from female fetus down syndrome pregnancies: a pilot study

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2519 DE 16/04/2019 POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2010, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: TOUCHLIGHT IP LIMITED (GB)